

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM828670

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	Termination and Release of Intellectual Property Security Agreement recorded at Reel 7855/Frame 0225		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
SLR Investment Corp.		07/31/2023	Corporation: MARYLAND
RECEIVING PARTY DATA			
Name:	Spectrum Pharmaceuticals, Inc.		
Street Address:	2 Atlantic Avenue, 6th Floor		
Internal Address:	Pilot House - Lewis Wharf		
City:	Boston		
State/Country:	MASSACHUSETTS		
Postal Code:	02110		
Entity Type:	Corporation: DELAWARE		
Name:	Allos Therapeutics, Inc.		
Street Address:	11080 Circle Point Road, Suite 200		
City:	Westminster		
State/Country:	COLORADO		
Postal Code:	80020		
Entity Type:	Corporation: DELAWARE		
Name:	Talon Therapeutics, Inc.		
Street Address:	7000 Shoreline Court, Suite 370		
City:	South San Francisco		
State/Country:	CALIFORNIA		
Postal Code:	94080		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 8			
Property Type	Number	Word Mark	
Serial Number:	97399084	ACCESS4ME	
Serial Number:	88381334	EXIANT	
Serial Number:	97060091	OZVONTI	
Serial Number:	97060082	POZENVEO	
Registration Number:	5302813	QAPZOLA	
Serial Number:	97211650	ROLVEDON	

CH \$215.00 97399084

Property Type	Number	Word Mark
Registration Number:	3414581	SPECTRUM PHARMACEUTICALS, INC.
Registration Number:	3139218	ALLOS

CORRESPONDENCE DATA

Fax Number: 9494754754

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 949-451-3800

Email: skann@gibsondunn.com

Correspondent Name: Stephanie Kann

Address Line 1: 3161 Michelson Drive

Address Line 2: Gibson, Dunn & Crutcher LLP

Address Line 4: Irvine, CALIFORNIA 92612

ATTORNEY DOCKET NUMBER: 89841-00020

NAME OF SUBMITTER: Stephanie Kann

SIGNATURE: /stephanie kann/

DATE SIGNED: 08/01/2023

Total Attachments: 9

source=Spectrum - IPSA Termination and Release (07.2023)#page1.tif

source=Spectrum - IPSA Termination and Release (07.2023)#page2.tif

source=Spectrum - IPSA Termination and Release (07.2023)#page3.tif

source=Spectrum - IPSA Termination and Release (07.2023)#page4.tif

source=Spectrum - IPSA Termination and Release (07.2023)#page5.tif

source=Spectrum - IPSA Termination and Release (07.2023)#page6.tif

source=Spectrum - IPSA Termination and Release (07.2023)#page7.tif

source=Spectrum - IPSA Termination and Release (07.2023)#page8.tif

source=Spectrum - IPSA Termination and Release (07.2023)#page9.tif

**TERMINATION AND RELEASE OF
INTELLECTUAL PROPERTY SECURITY AGREEMENT**

July 31, 2023

This Termination and Release of Intellectual Property Security Agreement dated as of the date first written above (this “*Release*”) is made with regard to that certain Intellectual Property Security Agreement entered into as of September 21, 2022 (as amended from time to time, “*Agreement*”) by SPECTRUM PHARMACEUTICALS, INC., a Delaware corporation (“*Spectrum*”), ALLOS THERAPEUTICS, INC., Delaware corporation (“*Allos*”), and TALON THERAPEUTICS, INC., Delaware corporation (“*Talon*”), and together with Spectrum and Allos, collectively, the “*Grantors*” and each individually a “*Grantor*”), in favor of SLR INVESTMENT CORP., a Maryland corporation (“*Agent*”), in its capacity as collateral agent for the Lenders. Capitalized terms not otherwise defined herein shall have the meanings ascribed to such terms in the Agreement.

WHEREAS, Agent agreed to make certain advances of money and to extend certain financial accommodations to the Grantors in the amounts and manner set forth in that certain Loan and Security Agreement, dated as of September 21, 2022, among Agent and the Grantors (as amended, restated, modified or supplemented from time to time, the “*Loan Agreement*”).

WHEREAS, pursuant the Agreement, which was recorded on September 22, 2022 at Vol. 15009 Doc 922 in the United States Copyright Office, the Grantors granted Agent a security interest in certain copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work thereof, whether published or unpublished and whether or not the same also constitutes a trade secret, now or hereafter existing, created, acquired or held, including without limitation forth on Exhibit A attached hereto (collectively, the “*Copyrights*”);

WHEREAS, pursuant the Agreement, which was recorded on September 22, 2002 at Reel 061179, Frame 0202 in the Patent division of the U.S. Patent and Trademark Office, the Grantors granted Agent a security interest in certain patents, patent applications and like protections including, without limitation, improvements, divisions, continuations, renewals, reissues, extensions, re-examination certificates, utility models, and continuations-in-part of the same, including without limitation the patents and patent applications set forth on Exhibit B attached hereto (collectively, the “*Patents*”);

WHEREAS, pursuant the Agreement, which was recorded on September 22, 2022 at Reel 7855, Frame 0225 in the Trademark division of the U.S. Patent and Trademark Office, the Grantors granted Agent a security interest in certain trademark and servicemark rights, whether registered or not, applications to register and registrations of the same and like protections, and the entire goodwill of the business of such Grantors connected with and symbolized by such trademarks, including without limitation those set forth on Exhibit C attached hereto (collectively, the “*Trademarks*”);

WHEREAS, the Grantors have paid and satisfied in full their Obligations under the Loan Agreement, and the parties desire to enter into this Release to confirm that Agent has released its security interests in and to the Intellectual Property Collateral and to expunge any recordation of the security interest insofar as it pertains to the Intellectual Property Collateral.

NOW, THEREFORE, for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Agent forever releases and discharges the entire security interest in and to all of the Intellectual Property Collateral, including the Copyrights, Patents and Trademarks.

Agent hereby agrees to execute such instruments, to take such other actions, and to give such further assurances as the Grantors shall reasonably request to terminate any security interest in the Intellectual Property Collateral pursuant to the Agreement and otherwise to effectuate the release of all recordations of such security interest in the Intellectual Property Collateral.

Agent acknowledges and agrees that the Grantors and its successors and assigns may rely upon this Release. Agent represents and warrants that it has not transferred or assigned all or any part of the security interest in the Intellectual Property Collateral to any third party, and that it has all necessary authority to execute this Release and grant the releases and discharges and all other rights set forth herein.

[Signature Page Follows]

IN WITNESS WHEREOF, Agent has caused this Release to be executed by a duly authorized officer thereunto as of the date first written above.

SLR INVESTMENT CORP., a Maryland corporation

By: 

Name: Anthony Stofino

Title: Authorized Signatory

Exhibit A
Copyrights

<u>Grantor</u>	<u>Description</u>	<u>Registration/ Application Number</u>	<u>Registration/ Application Date</u>
Allos Therapeutics, Inc.	Folotyn Package Insert	TX0007195509	2/10/2010

Exhibit B**Patents**

Grantor is SPECTRUM PHARMACEUTICALS, INC., except for #4 is TALON THERAPEUTICS, INC.

<u>Patent</u>	<u>Publication</u>	<u>Application</u>
1. METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR CONTRIBUTING TO THE TREATMENT OF SOLID TUMORS Inventors: ANIL GULATI		
8217010 Jul 10, 2012	20060211617 Sep 21, 2006	11360236 Feb 22, 2006
2. SENSITIZATION OF TUMOR CELLS TO RADIATION THERAPY THROUGH THE ADMINISTRATION OF ENDOTHELIN AGONISTS Inventors: ANIL GULATI, GURU REDDY, LUIGI LENZA		
8394757 Mar 12, 2013	20080318846 Dec 25, 2008	11845648 Aug 27, 2007
3. METHODS AND COMPOSITIONS FOR CONTRIBUTING TO THE TREATMENT OF CANCERS Inventors: ANIL GULATI, GURU REDDY, LUIGI LENZA		
8026216 Sep 27, 2011	20080253994 Oct 16, 2008	12101008 Apr 10, 2008
4. FORMULATIONS OF VITAMIN K ANALOGS FOR TOPICAL USE Inventors: CHRISTOPHER G. SALENTINE, KIERAN O'DONOGHUE		
8815953 Aug 26, 2014	20090234022 Sep 17, 2009	12381467 Mar 12, 2009
5. METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR CONTRIBUTING TO THE TREATMENT OF CANCERS Inventors: ANIL GULATI, GURU REDDY, LUIGI LENZA		
8030278 Oct 4, 2011	20090155206 Jun 18, 2009	12390376 Feb 20, 2009
6. METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR CONTRIBUTING TO THE TREATMENT OF CANCERS Inventors: ANIL GULATI, GURU REDDY, LUIGI LENZA		
8440620 May 14, 2013	20110315575 Dec 29, 2011	13220358 Aug 29, 2011

<u>Patent</u>	<u>Publication</u>	<u>Application</u>
7. METHODS AND COMPOSITIONS FOR CONTRIBUTING TO THE TREATMENT OF CANCERS Inventors: ANIL GULATI, GURU REDDY, LUIGI LENZA		
8349802 Jan 8, 2013	20110311481 Dec 22, 2011	13220373 Aug 29, 2011
8. METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR CONTRIBUTING TO THE TREATMENT OF SOLID TUMORS Inventors: ANIL GULATI		
8703709 Apr 22, 2014	20120245105 Sep 27, 2012	13491408 Jun 7, 2012
9. METHODS AND COMPOSITIONS FOR CONTRIBUTING TO THE TREATMENT OF CANCERS Inventors: ANIL GULATI, GURU REDDY, LUIGI LENZA		
8642026 Feb 4, 2014	20130101552 Apr 25, 2013	13707807 Dec 7, 2012
10. METHODS, COMPOSITIONS AND ARTICLES OF MANUFACTURE FOR CONTRIBUTING TO THE TREATMENT OF CANCERS Inventors: ANIL GULATI, GURU REDDY, LUIGI LENZA		
8729023 May 20, 2014	20130102543 Apr 25, 2013	13711519 Dec 11, 2012
11. SENSITIZATION OF TUMOR CELLS TO RADIATION THERAPY THROUGH ADMINISTRATION OF ENDOTHELIN AGONISTS Inventors: ANIL GULATI, GURU REDDY, LUIGI LENZA		
8957014 Feb 17, 2015	20130150649 Jun 13, 2013	13761043 Feb 6, 2013
12. TREATMENT OF PRIMARY AND METASTATIC CARCINOMA Inventors: ANTHONY W. TOLCHER, LUIGI LENZA		
9308235 Apr 12, 2016	20130338079 Dec 19, 2013	13890938 May 9, 2013
13. TREATMENT OF PRIMARY AND METASTATIC CARCINOMA Inventors: LUIGI LENZA, ANTHONY W. TOLCHER		
10022421 Jul 17, 2018	20160287660 Oct 6, 2016	15061821 Mar 4, 2016

<u>Patent</u>	<u>Publication</u>	<u>Application</u>
14. COMPOSITIONS COMPRISING DISODIUM LEVOFOLINATE Inventors: BAHMAN SHIMIAEI, RAMSHARAN SINGH		
11541012 Jan 3, 2023		16257684 Jan 25, 2019
15. METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX Inventors: GAJANAN BHAT, SHANTA CHAWLA		
11267858 Mar 8, 2022	20200377567 Dec 3, 2020	16428351 May 31, 2019
16. INHIBITORS OF MUTANT FAMILY TYROSINE-KINASES Inventors:		
11510922	20200261455 Aug 20, 2020	16757072 Apr 17, 2020
17. NOVEL METHODS OF TREATING NEUTROPENIA USING G-CSF PROTEIN COMPLEX Inventors: GAJANAN BHAT, SHANTA CHAWLA, JAE HYUK CHOI, EUN JUNG KIM, YU YON KIM, GYU HYAN LEE, HYESUN HAN		
None	20210008166 Jan 14, 2021	16996635 Aug 18, 2020
18. COMBINATION OF POZIOTINIB WITH CYTOTOXIC AGENT AND/OR OTHER MOLECULARLY TARGETED AGENT AND USE THEREOF Inventors: GURU REDDY		
None	20210145834 May 20, 2021	17250258 Dec 22, 2020
19. POZIOTINIB COMBINATIONS WITH AN ANTI-HER1, HER2 OR HER4 ANTIBODY AND METHODS OF USE THEREOF Inventors: GURU REDDY, SUNYOUNG JANG, JOOYUN BYUN		
None	20210260064 Aug 26, 2021	17250259 Dec 22, 2020
20. KITS AND METHODS FOR TREATING CANCERS Inventors: GURU REDDY		
None	20220040180 Feb 10, 2022	17275290 Mar 11, 2021

<u>Patent</u>	<u>Publication</u>	<u>Application</u>
21. CRYSTALLINE FORMS OF A QUINAZOLINE COMPOUND AND ITS HYDROCHLORIDE SALTS Inventors: HEE CHEOL KIM, KWEEHYUN SUH, JONG OUK BAEK, TAE HEE HA		
None	20220056011 Feb 24, 2022	17275382 Mar 11, 2021
22. NOVEL QUINAZOLINE EGFR INHIBITORS Inventors: PRASAD V. CHATURVEDULA		
None	20210353627 Nov 18, 2021	17278397 Mar 22, 2021
23. METHODS OF TREATING CHEMOTHERAPY INDUCED NEUTROPENIA USING FIXED DOSES OF G-CSF PROTEIN COMPLEX Inventors: JOHN A. BARRETT, SRIBALAJI LAKSHMIKANTHAN		
None	20220016212 Jan 20, 2022	17374302 Jul 13, 2021
24. METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX Inventors: GAJANAN BHAT, SHANTA CHAWLA		
None	20220153799 May 19, 2022	17586872 Jan 28, 2022
25. POZIOTINIB COMBINATION WITH VEGFR2 INHIBITORS AND METHODS OF USE THEREOF Inventors: GURU REDDY		
None	20220296598 Sep 22, 2022	17637304 Feb 22, 2022
26. METHODS OF TREATMENT USING G-CSF PROTEIN COMPLEX Inventors: SHANTA CHAWLA, GAJANAN BHAT		
None	20230027238 Jan 26, 2023	17781639 Jun 1, 2022

EXHIBIT C

Trademarks

<u>Description</u>	<u>Application Number</u>	<u>Application Date</u>	<u>Grantor</u>
ACCESS4ME	97/399,084	5/6/2022	Spectrum Pharmaceuticals, Inc.
EXIANT	88/381,334	4/11/2019	Spectrum Pharmaceuticals, Inc.
OZVONTI	97/060,091	10/5/2021	Spectrum Pharmaceuticals, Inc.
POZENVEO	97/060,082	10/5/2021	Spectrum Pharmaceuticals, Inc.
QAPZOLA	87/104,613 5,302,813	7/14/2016 10/3/2017	Spectrum Pharmaceuticals, Inc.
ROLVEDON	97/211,650	1/10/2022	Spectrum Pharmaceuticals, Inc.
SPECTRUM PHARMACEUTICALS, INC.	78/814,836 3,414,581	2/14/2006 4/22/2008	Spectrum Pharmaceuticals, Inc.
Allos	3139218	9/5/2006	Allos Therapeutics, Inc.